Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 13,670
+290 (2.17%)
At close: Dec 5, 2025
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 2.31B KRW in the quarter ending September 30, 2025, with 3.87% growth. This brings the company's revenue in the last twelve months to 14.41B, up 406.89% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
14.41B
Revenue Growth
+406.89%
P/S Ratio
11.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
164.30B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |